ReviewExpert review of proteomics2017
The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.
Review in Expert review of proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Proteomics of the heart.Physiological reviews · 2024Review
- Long-term prognostic value of high-sensitivity cardiac troponin-I in patients with idiopathic dilated cardiomyopathy.Open medicine (Warsaw, Poland) · 2023Article
- From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.International journal of molecular sciences · 2022Review
- The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity.Life (Basel, Switzerland) · 2022Review
- Review
- Determinants of Interindividual Variation in Exercise-Induced Cardiac Troponin I Levels.Journal of the American Heart Association · 2021Observational
- The Time Has Come for Quantitative Protein Mass Spectrometry Tests That Target Unmet Clinical Needs.Journal of the American Society for Mass Spectrometry · 2021Article
- Coronary Vascular Function and Cardiomyocyte Injury: A Report From the WISE-CVD.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Top-down proteomics: challenges, innovations, and applications in basic and clinical research.Expert review of proteomics · 2020Article
- Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum.Nature communications · 2020Article
- Troponin Aptamer on an Atomically Flat Au Nanoplate Platform for Detection of Cardiac Troponin I.Nanomaterials (Basel, Switzerland) · 2020Article
- Implications of the complex biology and micro-environment of cardiac sarcomeres in the use of high affinity troponin antibodies as serum biomarkers for cardiac disorders.Journal of molecular and cellular cardiology · 2020Review
- Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.Disease markers · 2020 · on this mapReview
- Interpol review of toxicology 2016-2019.Forensic science international. Synergy · 2020Review
- Cardioprotective effect of IGF-1 against myocardial ischemia/reperfusion injury through activation of PI3K/Akt pathway in ratsThe Journal of international medical research · 2019Article
- Advanced Evolution of Pathogenesis Concepts in Cardiomyopathies.Journal of clinical medicine · 2019Review
- Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?Sisli Etfal Hastanesi tip bulteni · 2019Article
- Analysis of cardiac troponin proteoforms by top-down mass spectrometry.Methods in enzymology · 2019Article
- Cardiac troponins may be irreversibly modified by glycation: novel potential mechanisms of cardiac performance modulation.Scientific reports · 2018Article
Corrections and comments
- Erratum issuedCorrigendum.2017
Authors and funding
6 authors.
Funding
Abstract
introductionThe troponin complex consists of three proteins that fundamentally couple excitation with contraction. Circulating cardiac-specific Troponin I (cTnI) serves as diagnostic biomarker tools for risk stratification of acute coronary syndromes and acute myocardial infarction (MI). Within the heart, cTnI oscillates between inactive and active conformations to either block or disinhibit actinomyosin formation. This molecular mechanism is fine-tuned through extensive protein modifications whose profiles are maladaptively altered with co-morbidities including hypertrophic cardiomyopathy, diabetes, and heart failure. Technological advances in analytical platforms over the last decade enable routine baseline cTnI analysis in patients without cardiovascular complications, and hold potential to expand cTnI readouts that include modified cTnI proteoforms. Areas covered: This review covers the current state, advances, and prospects of analytical platforms that now enable routine baseline cTnI analysis in patients. In parallel, improved mass spectrometry instrumentation and workflows already reveal an array of modified cTnI proteoforms with promising diagnostic implications. Expert commentary: New analytical capabilities provide clinicians and researchers with an opportunity to address important questions surrounding circulating cTnI in the improved diagnosis of specific patient cohorts. These techniques also hold considerable promise for new predictive and prescriptive applications for individualized profiling and improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.